Related Experiment Video
Updated: Jun 27, 2025
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Regulation of Molecular Biomarkers Associated with the Progression of Prostate Cancer
1Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland Eastern Shore, Princess Anne, MD 21853, USA.
Abstract:
Androgen receptor signaling regulates the normal and pathological growth of the prostate. In particular, the growth and survival of prostate cancer cells is initially dependent on androgen receptor signaling. Exposure to androgen deprivation therapy leads to the development of castration-resistant prostate cancer. There is a multitude of molecular and cellular changes that occur in prostate tumor cells, including the expression of neuroendocrine features and various biomarkers, which promotes the switch of cancer cells to androgen-independent growth. These biomarkers include transcription factors (TP53, REST, BRN2, INSM1, c-Myc), signaling molecules (PTEN, Aurora kinases, retinoblastoma tumor suppressor, calcium-binding proteins), and receptors (glucocorticoid, androgen receptor-variant 7), among others. It is believed that genetic modifications, therapeutic treatments, and changes in the tumor microenvironment are contributing factors to the progression of prostate cancers with significant heterogeneity in their phenotypic characteristics. However, it is not well understood how these phenotypic characteristics and molecular modifications arise under specific treatment conditions. In this work, we summarize some of the most important molecular changes associated with the progression of prostate cancers and we describe some of the factors involved in these cellular processes.
Insights
Prostate cancer growth relies on androgen receptor signaling. Treatment resistance involves molecular changes and biomarkers, leading to androgen-independent growth and tumor heterogeneity.
Area of Science:
- Oncology
- Molecular Biology
- Urology
Background:
- Androgen receptor (AR) signaling is crucial for prostate cancer (PCa) cell growth and survival.
- Androgen deprivation therapy (ADT) induces castration-resistant prostate cancer (CRPC).
- CRPC development involves significant molecular and cellular alterations, including neuroendocrine differentiation and biomarker expression.
Purpose of the Study:
- To summarize key molecular changes in prostate cancer progression.
- To describe factors contributing to cellular processes driving CRPC.
- To elucidate the mechanisms behind phenotypic heterogeneity in prostate cancer under specific treatments.
Main Methods:
- Review of literature on molecular and cellular changes in prostate cancer.
- Analysis of biomarkers associated with castration resistance.
- Discussion of factors influencing tumor microenvironment and genetic modifications.
Main Results:
- Expression of specific transcription factors (e.g., TP53, BRN2, c-Myc) and signaling molecules (e.g., PTEN, Aurora kinases) are implicated in CRPC.
- Alterations in receptors, such as glucocorticoid receptors and AR-variant 7, contribute to treatment resistance.
- Genetic modifications, therapeutic interventions, and tumor microenvironment changes drive PCa heterogeneity.
Conclusions:
- Understanding the molecular landscape of CRPC is vital for developing targeted therapies.
- Biomarker identification is essential for predicting treatment response and disease progression.
- Further research is needed to clarify the interplay of factors leading to phenotypic plasticity in prostate cancer.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:23Regulation of Expression at Multiple Steps